Last reviewed · How we verify
Levodopa tablet
At a glance
| Generic name | Levodopa tablet |
|---|---|
| Sponsor | Tel-Aviv Sourasky Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Levodopa for Diabetic Retinopathy (PHASE2)
- A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants (PHASE1)
- A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations (PHASE2)
- Dopaminergic Therapy for Anhedonia - 2 (PHASE4)
- Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm (PHASE1, PHASE2)
- Carbidopa-levodopa in Neovascular AMD (PHASE2)
- Dose Ranging Study of Carbidopa-levodopa (PHASE2)
- Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levodopa tablet CI brief — competitive landscape report
- Levodopa tablet updates RSS · CI watch RSS
- Tel-Aviv Sourasky Medical Center portfolio CI